text stringlengths 26 6.34k |
|---|
PMID title abstract labels |
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. BACKGROUND: Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)-based detection of molecular residual disease may identify patients at high risk for recurrence after cystectomy who can be... |
The Urinary Microbiota and the Gut-Bladder Axis in Bladder Cancer. The human bladder hosts a resident, low-biomass microbial community (urobiota) that has only become the subject of intense investigation in the last 15 years. The advantages that the urobiota may confer to the bladder, in contrast to the microbiota of ... |
Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48. BACKGROUND: Immune checkpoint inhibitors have shown limited response rates in bladder cancer. RC48-antibody-drug conjugate (ADC) shows potential for combination with immune checkpoint inhibitors. This study aimed to elucid... |
Metabolite-mediated mechanisms linking the urinary microbiome to bladder cancer. Bladder cancer is the most common malignancy of the urinary tract and is a major health burden globally. Recent advances in microbiome research have revealed that the urinary tract harbors a resident microbial community, overturning the l... |
Cancer-associated fibroblast derived CXCL14 drives cisplatin chemoresistance by enhancing nucleotide excision repair in bladder cancer. BACKGROUND: A significant challenge in bladder cancer treatment is primary chemoresistance, in which cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME) play a pi... |
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. BACKGROUND: Patients with high-risk non-muscle-invasive bladder cancer (NMIBC) often have recurrence or progression after transurethral resection of blad... |
Neuroendocrine tumours of the urinary bladder: recent advances. Small cell carcinoma is the most frequently encountered neuroendocrine tumour (NET) of the urinary bladder, and it may present as either pure or in combination with urothelial carcinoma or other histological subtypes. Large cell neuroendocrine carcinoma i... |
Dynamic changes of urinary microbiota in patients with bladder cancer after surgery and its clinical significance. Bladder cancer is one of the most common malignancies of the urogenital system, with a high incidence and mortality. The treatment of bladder cancer is diverse, with surgical treatment being the most comm... |
Molecular pathology of bladder cancer. Significant progress has been achieved in elucidating the molecular underpinnings of bladder cancer initiation and progression. Translational research has identified mutations in chromatin-modifying genes such as KMT2D and KDM6A, which facilitate colonization of larger regions of... |
Contemporary management of metastatic urothelial carcinoma. Urothelial carcinoma, the most common malignancy of the urinary tract, presents a significant challenge, particularly in its metastatic stage, where prognosis remains poor despite advancements in treatment. Historically, platinum-based chemotherapy has been t... |
[Bladder cancer in geriatric patients]. Bladder cancer is one of the most commonly diagnosed cancers, especially in older people. Bladder cancer belongs to urothelial carcinomas, which can also occur in other parts of the urinary tract (also at the same time). The most common symptom of bladder cancer is hematuria. Bl... |
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer. PURPOSE: The evolving treatment landscape of muscle-invasive bladder cancer (MIBC) increasingly warrants novel trial design to evaluate perioperative strategies aimed at bladder preservation. To es... |
Circulating tumor DNA and urinary tumor DNA: useful biomarkers for bladder cancer detection. INTRODUCTION: Bladder cancer (BC), a prevalent urinary system malignancy, presents challenges for early diagnosis because of its nonspecific symptoms and late-stage presentation, leading to poor prognosis. Liquid biopsy, parti... |
CCDC137 knockdown suppresses bladder cancer progression by downregulating SCD. BACKGROUND: The Coiled-coil domain-containing (CCDC) family, due to its unique protein structural domain and broad involvement in diverse biological processes, has emerged as a focus in oncology research. Nevertheless, its clinical signific... |
Mitomycin Intravesical Solution: First Approval. Mitomycin intravesical solution (ZUSDURI(TM)), a hydrogel formulation of the DNA synthesis inhibitor mitomycin, has been developed by UroGen Pharma, Inc. for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) via intravesical i... |
ROS-responsive resiquimod prodrug nanoparticles for macrophage reprogramming and enhanced immune checkpoint inhibitor therapy in bladder cancer. Bladder cancer remains a formidable challenge, especially for patients who fail to respond adequately to immune checkpoint inhibitors (ICIs). The suboptimal efficacy of curre... |
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial. Nivolumab monotherapy has been approved for the adjuvant treatment of adult patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection ... |
Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs. Upper tract urothelial carcinoma (UTUC) and urinary bladder cancer (UBC), though histologically similar, differ molecularly, prompting interest ... |
Advances in the immunological microenvironment and immunotherapy of bladder cancer. Bladder cancer remains a significant global health challenge, particularly affecting male populations. While radical cystectomy and chemotherapy have been mainstays of treatment, their substantial morbidity and impact on quality of lif... |
SEOM-SOGUG clinical guideline for urothelial cancer (2025). This clinical guideline provides evidence-based recommendations for the diagnosis, staging, and management of bladder cancer across all disease stages. In these guidelines (updated in 2025), we summarize current evidence and available therapies for the medica... |
Management of clinical stage T3/T4 bladder cancer: a review. INTRODUCTION: Bladder cancer is a common malignancy in the United States and while the majority are non-muscle invasive at diagnosis, those with muscle-invasive and locally advanced disease can be challenging to manage. In addition, the prognosis is poorer i... |
Virus-induced APOBEC3 transmutagenesis in bladder cancer initiation. "Carcinogenesis in human urothelium is driven by a high burden of mutations caused by the antiviral ""APOBEC3"" (apolipoprotein B mRNA editing enzyme, catalytic subunit-like 3) cytosine deaminase enzymes; however, there is no established viral etiolo... |
Urinary microbiome in non-muscle invasive bladder cancer: impact of sample types and sex differences. BACKGROUND: Previous research on urinary microbiomes in bladder cancer patients has yielded inconsistent results, highlighting the need for further investigation. This study aims to analyze microbiome dysbiosis in bla... |
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274. BACKGROUND: Despite surgery, recurrence rates remain high in muscle-invasive urothelial carcinoma (MIUC). The phase III randomized, double-blind, multicenter CheckMate 274 trial c... |
Transglutaminase 2 facilitates metastasis of basal-like bladder cancer by sustaining MVP-mediated MAPK/ERK1/2 signaling activation. Basal-like bladder cancer is a subtype of bladder cancer (BC) with a high risk of invasion and metastasis, for which there are currently no approved or clinically validated targeted thera... |
Clinical applications of bladder magnetic resonance imaging: Beyond the VI-RADS® classification. Bladder cancer is a cause for serious concern due to its high prevalence and the considerable challenges it poses in terms of morbidity, costs, and mortality. In recent years, magnetic resonance imaging (MRI) of the bladde... |
Multi-omics integrative analysis of the mechanisms linking environmental pollutant exposure to bladder cancer pathogenesis. "Bladder cancer (BCa), the most prevalent malignancy of the urinary system, is strongly associated with environmental factors including smoking and industrial chemical exposure. Although previous... |
Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer. Tumor gene alterations can serve as predictive biomarkers for therapy response. The nucleotide excision repair (NER) helicase ERCC2 carries heterozygous missense mutations in approximately 10% of bladder tumors, and... |
Enfortumab vedotin-induced bullous dermatitis. Enfortumab vedotin is a first-in-class antibody-drug conjugate used in the treatment of locally advanced or metastatic urothelial carcinoma. A range of cutaneous adverse events has been reported with enfortumab vedotin use. Nectin-4, a transmembrane protein overexpressed ... |
Emotional stress: a prominent factor positively related to the onset and recurrence of bladder cancer as revealed by NHANES and a Chinese database. BACKGROUND AND OBJECTIVE: Bladder cancer and emotional stress are both common physiologic problems, with few published studies and a lack of studies with large samples dis... |
FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma. Dysregulation of fibroblast growth factor receptor (FGFR) signaling contributes to tumorigenesis and FGFRs have been clinically approved as treatment targets for FGFR inhibitor (FGFRi) in urothelial carcinoma (UC). The present study a... |
Mechanisms for fibrate lipid-lowering drugs in enhancing bladder cancer immunotherapy by inhibiting CD276 expression. OBJECTIVE: This study aimed to investigate the growth-inhibitory effects of fibrate lipid-lowering drugs on bladder cancer cells and their underlying mechanisms, with a focus on exploring how fenofibra... |
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey. BACKGROUND: Enfortumab vedotin combined with pembrolizumab (EV-P) has become the new standard first-line therapy for patients with advanced urothelial carcinoma (aUC), based on its superior efficacy over platinum-based chemothera... |
Urinary biomarkers for immunotherapy response in urothelial carcinoma: current status and future outlook. INTRODUCTION: Immunotherapy treatments, such as intravesical Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) and systemic immune checkpoint inhibitors (ICIs) for all stages are centra... |
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. With the approval of the antibody-drug conjugate enfortumab vedotin (EV), NECTIN4 has emerged as a bona fide therapeutic target in urothelial carcinoma (UC). Here, we report the development o... |
Urine cf-nucleosomes: A non-invasive window into human physiology and disease. Urine contains fragments of cell-free DNA (cfDNA) that offer molecular insights into processes within the urinary system and the body. It remains unclear whether these fragments exist as chromatin and retain chromatin modifications from the... |
Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies. Low-grade non-muscle invasive bladder cancer is a specific category of bladder cancer with a favourable prognosis; however, its management presents several challenges. The risk of stage progression is very l... |
YTHDC2 suppresses bladder cancer by inhibiting SOX2-mediated tumor plasticity. Pluripotent cancer stem cells play a pivotal role in inducing phenotypic plasticity across various cancer types, including bladder cancer. This plasticity, crucial for cancer progression, is largely regulated by epigenetic modifications inc... |
Lactate-driven lactylation of HNRNPA1 orchestrates PKM2 splicing and glycolytic reprogramming in bladder cancer. BACKGROUND: Lactylation, a recently identified post-translational modification derived from lactate, has emerged as a regulator of tumor metabolism. However, its functional relevance and molecular targets i... |
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial. PURPOSE: To evaluate the efficacy and safety of BL-B01D1, a potential first-in-class epidermal growth factor receptor (EGFR)-human EGFR 3 bispecific antibody-drug conjugated (ADC) with Ed-04... |
Sex and smoking bias in the selection of somatic mutations in human bladder. Men are at higher risk of several cancer types than women(1). For bladder cancer the risk is four times higher for reasons that are not clear(2). Smoking is also a principal risk factor for several tumour types, including bladder cancer(3). A... |
Advancing Bladder Cancer Management: The Role of Neoadjuvant and Adjuvant Therapies and Biomarkers in Muscle Invasive Bladder Cancer. The management of muscle-invasive bladder cancer (MIBC) is evolving rapidly, with the integration of neoadjuvant and adjuvant therapies and biomarker-driven patient selection now essent... |
Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer: mechanisms, clinical evidence, and practical implementation. PURPOSE OF REVIEW: Gene therapy has emerged as an attractive bladder-sparing strategy for patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bl... |
Single-cell and spatial transcriptomic analysis reveal cellular heterogeneity and cancer cell-intrinsic major histocompatibility complex II expression in urothelial carcinoma. Muscle-invasive (MI) urothelial carcinoma (UC) is a clinically challenging malignancy with a poor prognosis. Understanding the cellular dynamic... |
Extracellular Vesicle-Packaged MIR4435-2HG Facilitates Cigarette Smoke-Induced Bladder Cancer Progression through Enolase 1-Dependent Glycolytic Reprogramming. Epidemiological studies have reported that cigarette smoking promotes bladder cancer progression, but the corresponding biological mechanisms must be elucidate... |
CT-based radiomics signature of visceral adipose tissue for prediction of early recurrence in patients with NMIBC: a multicentre cohort study. INTRODUCTION: The objective of this study is to investigate the predictive ability of abdominal fat features derived from computed tomography (CT) to predict early recurrence w... |
MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment. BACKGROUND: Mucosa-associated invariant T (MAIT) cells represent a unique population of innate-like T lymphocytes capable of detecting non-peptide antigens in the context of monomorphic antigen-presenting molecu... |
TRIM29 promotes bladder cancer invasion by regulating the intermediate filament network and focal adhesion. Bladder cancer is a common malignancy whose lethality is determined by invasive potential. We have previously shown that TRIM29, also known as ATDC, is transcriptionally regulated by TP63 in basal bladder cancer... |
Evaluating diagnostic performance of urinary biomarkers in the surveillance of non-muscle invasive bladder carcinoma: A systematic review. PURPOSE: Urinary biomarkers have been proposed to play an integral role in detecting recurrent non-muscle invasive bladder carcinoma (NMIBC). This review delineates the diagnostic ... |
Bladder cancer immunotherapy parallel advances in BCG optimization and next-generation vaccine platforms. Bladder cancer (BCa) remains a significant global health challenge with rising incidence and suboptimal outcomes in advanced stages. Although immunotherapy for urological cancers is not a new treatment, recent cli... |
AI-informed computational pathology classifier predicts outcomes across treatment modalities in muscle-invasive urothelial carcinoma. Urothelial carcinoma (UC) is one of the leading causes of cancer-related mortality, and effective, scalable biomarkers for treatment planning remain limited. We present UC-TIL, an artif... |
Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis. Enfortumab vedotin (EV), targeting Nectin-4, is effective in advanced urothelial carcinoma but frequently causes skin toxicities. This study examined the possible contribution of prior immune checkpoint inhibitor (ICI) t... |
Neutrophil extracellular traps-STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer. BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed the treatment strategy for bladder cancer (BLCA), but primary resistance still occurs in most patients. Recent evidence suggests that neu... |
Treatment strategies for cisplatin-ineligible metastatic bladder cancer: Emerging therapies and future perspectives. Recently, the combination of enfortumab vedotin and pembrolizumab has been recommended as the preferred first-line therapy for metastatic or locally advanced urothelial carcinoma owing to its substantia... |
Aberrant KIF26B expression promotes bladder cancer progression through driving NSUN2 nuclear localization. Abnormal expression of kinesins has been observed in several types of cancer. The present study provided the first evidence that KIF26B could induce RNA m(5)C modification in bladder cancer (BCa). Detailly, KIF26... |
Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle Invasive Bladder Cancer. BACKGROUND: Bacillus Calmette-Guérin (BCG) is the standard adjuvant therapy for high-risk non-muscle invasive bladder cancer (NMIBC), yet treatment failure occurs in 30% to 40% of patients. Those with BCG-unrespo... |
Self-driven electrical triggering system activates tunneling nanotube highways to enhance drug delivery in bladder cancer therapy. Bladder cancer ranks among the most prevalent malignancies affecting the urinary system worldwide. Despite advances in treatment, poor drug penetration and uncontrolled release continue to... |
Molecular classification of nonurothelial histologic subtypes of bladder cancer. Molecular subtyping of bladder cancer facilitates the development of personalized treatments and predict responses based on disease biology. Classically, bladder cancers have been classified into basal and luminal molecular subtypes. Howe... |
β2-integrins as biomarkers in urothelial cancer. β2-integrins are a family of adhesion proteins expressed in immune cells that play multiple roles in anti-tumor immunity. β2-integrins regulate tumor infiltration of anti-tumorigenic immune cells such as cytotoxic CD8 + T cells and NK cells. However, they also regulate ... |
Systemic immunotherapy for BCG unresponsive nonmuscle-invasive bladder cancer. PURPOSE OF REVIEW: Treatment of Bacillus Calmette-Guérin (BCG)-refractory nonmuscle-invasive bladder cancer (NMIBC) is a significant clinical problem, with limited bladder-sparing strategies. The following review aims to show the recent adv... |
LDHA facilitates immune escape in bladder cancer through H4K5 lactylation-dependent upregulation of PD-L1. Metabolic reprogramming, characterized by hyperactive glycolysis, is a hallmark of bladder cancer (BCa) progression. Here, we identify lactate dehydrogenase A (LDHA) as a central metabolic node coupling glycolyti... |
Construction of a gene-metabolite-microbiome regulatory network reveals novel therapeutic targets in bladder cancer through multi-omics analysis. BACKGROUND: Bladder cancer (BLCA) is a prevalent malignancy with substantial consequences for patient health. This study aimed to elucidate the underlying mechanisms of BLCA... |
Characterization of cancer-related fibroblasts in bladder cancer and construction of CAFs-based bladder cancer classification: insights from single-cell and multi-omics analysis. "BACKGROUND: Bladder cancer (BLCA) continues to be a significant cause of cancer mortality in the urinary tract, with therapeutic resistance... |
Grading of bladder cancer: updates, controversies and practical solutions. Bladder cancer grading provides important prognostic information to clinicians, and the assigned grade is used as a variable in risk stratification models. There have been multiple proposed grading schemes over the last century, with the most w... |
Unraveling the dual role of METTL3-mediated m(6)A RNA modification in bladder cancer: mechanisms, therapeutic vulnerabilities, and clinical implications. Bladder cancer (BC) remains challenging due to its recurrence and metastasis, with METTL3-mediated m(6) A RNA modification emerging as a key oncogenic driver. This r... |
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study. INTRODUCTION: Enfortumab vedotin-ejfv (EV), an antibody-drug conjugate approved for advanced urothelial carcinoma (aUC), has limited real-world safety da... |
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC). BACKGROUND: Standard treatment of high-risk non-muscle-invasive bladder cancer (... |
Bladder Cancer and Vesical Imaging-Reporting and Data System: An Updated Review. Bladder cancer is a prevalent malignancy with a significant societal burden. Treatment strategies and prognosis are largely determined by the degree of local tumor invasion into the bladder wall. The Vesical Imaging-Reporting and Data Sys... |
SQLE drives bladder cancer progression by boosting mitochondrial oxidative phosphorylation. Bladder cancer (BCa) remains a prevalent malignancy with limited therapeutic options. Although cholesterol elevation links to BCa progression, the specific role of cholesterol metabolism remains unclear. Here, we demonstrate th... |
The role of lasers in the management of bladder tumors. INTRODUCTION: The objective of this review is to assess the role of laser technology in the management of non-muscle-invasive bladder cancer (NMIBC). METHODS: A literature review was conducted using the Medline database with the keywords bladder and laser. Releva... |
Targeted therapies for Bacillus Calmette-Guérin unresponsive nonmuscle-invasive bladder cancer: a narrative review. PURPOSE OF REVIEW: The purpose of this narrative review is to compile the latest available evidence on targeted therapy in the management of Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive... |
MFSD12, transcriptionally regulated by PLAGL2, promotes bladder cancer progression. Bladder cancer (BLCA) is one of the most common malignant tumors of the urinary system. Identification of novel molecular signaling targets for the tumorigenesis of BLCA is important. Data from the Gene Expression Omnibus (GEO) and The... |
STAG2 regulates polycomb and differentiation in urothelial precursors and bladder cancer. The STAG2 tumor suppressor gene is commonly inactivated by mutations in a wide range of common cancer types. STAG2 encodes a component of the cohesin complex, which controls sister chromatid cohesion and 3D genome organization. I... |
MiR-20a-5p Inhibits Bladder Cancer Proliferation and Migration by Targeting KPNA2. Bladder cancer (BC) is one of the 10 most common cancers in the world, and its recurrence and metastasis are the main causes of death in BC patients. Exploring the molecular mechanisms of BC pathogenesis and searching for new prognostic... |
The lncRNA MIR4435-2HG Modulates Bladder Cancer Progression and Ferroptosis Through the IQGAP3/Ras/ERK/CREB Pathway. Bladder cancer (BCa) is characterized by high incidence and recurrence rates, and its development is closely related to ferroptosis. However, the regulatory mechanism of MIR4435-2HG in BCa and ferroptos... |
Comprehensive Assessment of Tumor Stromal Heterogeneity in Bladder Cancer by Deep Learning and Habitat Radiomics. RATIONALE AND OBJECTIVES: Tumor stromal heterogeneity plays a pivotal role in bladder cancer progression. The tumor-stroma ratio (TSR) is a key pathological marker reflecting stromal heterogeneity. This st... |
The promising arsenal of ferroptosis inducers in bladder cancer. Bladder cancer ranks among the most common malignancies of the urinary system. Despite continuous advances in treatment technologies, the risk of tumor progression and metastasis remains high due to its extreme heterogeneity, resulting in poor patient pr... |
RNA m(5)C Modifications in the Development and Prognosis of Muscle-Invasive Bladder Cancer. The m(5)C RNA modifications have been implicated in the pathogenesis of urothelial carcinoma and hold potential as prognostic biomarkers for muscle-invasive bladder cancer (MIBC) patients. In this study, we developed an MIBC-ri... |
Methylparaben and propylparaben promote bladder cancer invasion via MMP2 and PPARG modulation. OBJECTIVE: Parabens, esters of p-hydroxybenzoic acid, are widely utilized as antimicrobial preservatives in consumer products. While increasing evidence implicates parabens in tumor progression across cancers, their role and... |
Targeting PSMB5-induced PANoptosis in bladder cancer: multi-omics insights and TCM candidate discovery. BACKGROUND: Bladder cancer (BLCA) is among the most common malignancies worldwide, with significant mortality rates. The function of PANoptosis in BLCA, as a controlled process of programmed cell death, remains larg... |
Mitochondria-located circRCP regulates redox homeostasis via stabilizing LRPPRC/SLIRP complex to promote bladder urothelial carcinoma tumorigenesis. The function of circular RNAs (circRNAs) located within the mitochondria in the pathogenesis of urothelial carcinoma of the bladder (UCB) remains largely unexplored. This... |
Management of Bladder Cancer During Pregnancy: A Narrative Review. "BACKGROUND/AIM: Bladder cancer (BC) during pregnancy is extremely rare. Therefore, the epidemiological understanding of BC during pregnancy remains limited, and the literature consists mostly of isolated case reports. This review aimed to provide an u... |
Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma. BACKGROUND/AIM: Enfortumab vedotin (EV) is an antibody-drug conjugate approved for metastatic urothelial carcinoma (mUC); however, clinical data in elderly patients are limited. Given the increasing use of EV as a first... |
Effects of Avelumab Maintenance on Advanced Urothelial Carcinoma: A Real-World Multicenter Study. OBJECTIVES: Oncological outcomes in patients with urothelial carcinoma treated with avelumab maintenance therapy or conventional platinum-based first-line chemotherapy were compared in real-world practice. METHODS: Outcom... |
Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder cancer: A network meta-analysis. Muscle-invasive bladder cancer (MIBC) is a highly aggressive disease requiring multimodal treatment. While neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is standard, many patients experien... |
Optimizing Tissue Sampling Timing for Accurate Gene Expression Analysis. The reliability of molecular diagnostic and prognostic tools is contingent on the quality of biospecimens, which are often collected during surgical procedures. This study investigated the impact of surgical manipulation on gene expression in the... |
Dysregulated mitochondrial energy metabolism drives the progression of mucosal field effects to invasive bladder cancer. Multiplatform mutational and gene expression profiling complemented with proteomic and metabolomic spatial mapping were used on the whole-organ scale to identify the molecular profile of bladder can... |
[Primary lymphomas in urinary bladder: a clinicopathological analysis of 23 cases]. "Objective: To investigate the clinicopathological features, diagnosis and differential diagnosis of primary bladder lymphoma. Methods: A retrospective study was conducted on 23 cases of primary bladder lymphoma diagnosed at Beijing Fr... |
Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy. OBJECTIVES: To compare survival and oncological outcomes of cisplatin-ineligible patients (Cis-I) and cisplatin-eligible (Cis-E) patients with muscle-invasive bladder cancer (MI... |
Multi-DECT Image-based Interpretable Model Incorporating Habitat Radiomics and Vision Transformer Deep Learning for Preoperative Prediction of Muscle Invasion in Bladder Cancer. RATIONALE AND OBJECTIVES: The research aims to evaluate the effectiveness of a multi-dual-energy CT (DECT) image-based interpretable model th... |
Transient receptor potential vanilloid type 4 channels mediate bladder cancer cell proliferation, migration, and chemoresistance. Bladder cancer (BLCA) is the second most common urologic cancer in the United States and worldwide and mostly affects the aging population. Despite several ongoing clinical trials, treatmen... |
KDM6A deficiency promotes 5-aminolevulinic acid-mediated photodynamic therapy resistance in bladder cancer by suppressing ROS accumulation. BACKGROUND: Non-muscle invasive bladder cancer (NMIBC) frequently recurs after transurethral resection of bladder tumors, necessitating a novel therapeutic approach. 5-Aminolevuli... |
State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder Cancer. Antibody-drug conjugates (ADCs) have revolutionized the treatment landscape for advanced bladder cancer, particularly enfortumab vedotin and trastuzumab deruxtecan, which target Nectin-4 and human epidermal growth factor recepto... |
DNA Methylation in Bladder Cancer: Diagnostic and Therapeutic Perspectives-A Narrative Review. Bladder cancer pathogenesis is closely linked to epigenetic alterations, particularly DNA methylation and demethylation processes. Environmental carcinogens and persistent inflammatory stimuli-such as recurrent urinary tract... |
Effect of neoadjuvant chemotherapy on years of life lost in radical cystectomy-treated T2N0M0 bladder cancer patients. INTRODUCTION: Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is standard of care for T2N0M0 urothelial carcinoma of urinary bladder (UCUB) patients. However, the effect of NAC on y... |
Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer. PURPOSE: In QUILT-3.032, the efficacy of interleukin-15 rece... |
Glutamine metabolism reprogramming promotes bladder cancer progression via PYCR1: a multi-omics and functional validation study. BACKGROUND: Bladder cancer (BLCA) is a prevalent malignancy worldwide, with advanced stages linked to poor prognosis. Although immune checkpoint inhibitors (ICIs) show clinical promise in tr... |
Molecular Heterogeneity and Clinicopathologic Correlations in Inflammatory Myofibroblastic Tumors of the Urinary Bladder: A Study of 20 Cases With Predominant FN1::ALK Fusions and Novel Kinase Rearrangements. Inflammatory myofibroblastic tumors (IMTs) of the urinary bladder are rare mesenchymal neoplasms with an incom... |
Non-invasive bladder cancer detection: Identification of a urinary volatile biomarker panel using GC-MS metabolomics and machine learning. Early detection of bladder cancer (BC) remains a major clinical challenge due to the limitations of current diagnostic methods, which are often invasive, expensive, or insufficient... |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 19